Biotage acquires Astrea Bioseparations

By Rachel Arthur

- Last updated on GMT


Related tags Biotage Chromatography Uk Us Sweden purification chromatography resins

Biotage will acquire Astrea Bioseparations, a chromatography solutions provider, from Gamma Biosciences: extending its chromatography franchise into the bioprocessing market for biologics and advanced therapeutic customers.

The agreement values Astrea – which is headquartered in Cambridge, UK, with manufacturing facilities in the UK and US – at around $190m.

Astrea Bioseparations is a provider of process chromatography solutions, including columns, resins, and nanofiber purification technology for life sciences and other adjacent industries. Its products are used in the manufacture of more than 20 FDA approved treatments, while it has a pipeline oriented towards the purification of novel modalities.

'Rich, near-term pipeline'

Described as a ‘global impact tech company’ with products for customers in drug discovery, development, diagnostics and analytical testing, Biotage has set out its ambitions to grow its offering in the biologics and novel therapeutics space, noting this is where it sees major advancements taking place.

“With Astrea becoming part of Biotage, we have taken a huge leap in fulfilling that vision,” said Torben Jörgensen, Chairman of the Board at Biotage.

The acquisition will extend the Uppsala, Sweden-headquartered company’s chromatography franchise into the higher-growth and larger bioprocessing segment, as well as increasing exposure to biologics and advanced therapeutic customers.

“Importantly, Astrea strengthens Biotage’s financial profile through its attractive organic growth rate, higher gross margins, and significant exposure to recurring consumables-based revenues,” says Biotage.

“In addition, the acquisition brings a rich, near-term pipeline of new product launches across chromatography resins, nanofiber-based membranes, and columns.”


Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more